Updated 22 July 2021.
2020 completely rocked the schedule of clinical operations conferences by the efforts to stave off the spread of COVID-19. Nearly every conference went virtual. Now with a vaccine on the horizon, we are all hoping to have at least some face to face clinical trial conferences in
Peju Oshisanya joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss diversity and inclusion in clinical trials. An experienced clinical operations specialist and a strong advocate for data diversity, Peju shares her insight into the health sciences industry, evaluates opportunities for improvement, and illuminates the
If it shocks you to hear that clinical trials are getting more complex, you haven’t been paying attention. Specifically, we’re collecting more endpoints. We’re performing more procedures. We’re increasing nearly every executional variable, like the number of countries, the number of sites, the number of visits per patient, and the
By all accounts, the cost of clinical trials continues to rise. We hear reasons that include increasing protocol complexity, patient recruitment struggles, or regulatory challenges. And we shrug our shoulders. Most of us accept these rising costs and obstacles as a given.
But - why?
If you could predict the future problems
The decentralized clinical trial is one of the most talked-about emerging trends in the life sciences industry. These sorts of clinical trials present immense benefits, as we wrote about in a recent blog.
If executed well, the decentralized clinical trial design could both reduce resource consumption and accelerate treatments arrival to
You have a clinical trial starting soon. Are you working with a contract research organization, or at least planning to do so? Probably. In 2020, the ACRP estimated that 70% of clinical trials would involve sponsors working with CROs. And, as a result, 100% of those sponsors will encounter some
Ken Getz joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss the growing complexity in clinical trial protocols. The Director of the Tufts Center for the Study of Drug Development and a Research Professor at the Tufts University School of Medicine, Ken shares his insights
Rebecca Setta joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss effective management of sites and teams through arduous clinical trials.
Rebecca shares how she’s kept her team motivated and productive in spite of the added burdens imposed by the pandemic, and why she’s excited
There are still a lot of challenges facing pharmaceuticals, med tech, and biotech companies that seek to begin a clinical trial post-COVID. But the obstacles aren’t stopping them. At time of writing, over 500 companies have a Phase II or Phase III clinical trial startup planned in the next 12
Increased diversity. Faster enrollment. Reduction in costs. These are just a few of the myriad benefits of the virtual clinical trial touted by CROs and solution providers. But are you ready for a truly virtual clinical trial? If not, is a hybrid clinical trial realistic? And what is a decentralized